BlinkLab

BlinkLab operates at the intersection of digital diagnostics, neuroscience software, and clinical research. Its core differentiation is the attempt to convert an ordinary smartphone into a remote neurobehavioral testing device, using short videos, auditory and visual stimuli, computer vision, and facial-response measurements rather than dedicated laboratory hardware or face-mounted sensors. That approach gives BlinkLab a different delivery model from conventional autism and ADHD assessments, which generally depend on specialist appointments, structured observation, and clinic-based workflows. The company also extends beyond a single diagnostic product: the BlinkLab Research Platform supports customizable experiments, automated facial-response tracking, monitoring, visualization, and trial-level analysis. Dx1 focuses on autism screening, while Dx2 is aimed at ADHD assessment. BlinkLab’s position is strengthened by its ninth-site U.S. FDA trial network, Morocco deployment, and one granted patent, but its commercial and regulatory maturity remains less established than that of larger diagnostic developers and established clinical-assessment providers.

BlinkLab shows a clear transition from early research commercialization to public-company-funded clinical expansion. The company raised a $0.88M equivalent Seed round announced on Nov 15, 2021, then completed its ASX listing on Apr 5, 2024. Its major inflection point came with the A$17.5M, approximately $12.49M, post-IPO equity raise announced on Apr 15, 2026. Management indicated that the capital would support the launch of its autism diagnostic aid and expansion of its ADHD program. Product and clinical development accelerated in 2025 and 2026: BlinkLab completed a U.S. pilot autism study in October 2025, expanded its pivotal FDA trial network to nine sites by February 2026, and announced the pivotal trial in March. The March 2026 Morocco deployment represents an early test of international scale, while the July 2026 update broadened the stated opportunity beyond the flagship autism program. The company reports seven current positions and added an iOS developer in September 2025. Growth remains dependent on clinical validation, regulatory clearance, adoption by healthcare systems, and conversion of research capabilities into recurring commercial use.